about
Adaptive clinical trial designs for European marketing authorization: a survey of scientific advice letters from the European Medicines AgencySharing clinical trial data on patient level: opportunities and challengesOptimizing Trial Designs for Targeted Therapies"Threshold-crossing": A Useful Way to Establish the Counterfactual in Clinical Trials?Maximum type 1 error rate inflation in multiarmed clinical trials with adaptive interim sample size modificationsThe reassessment of trial perspectives from interim data--a critical view.Degeneration and Instability and the Relation to Patients' Function Late After Lumbar Disc Surgery: Data from a 12-Year Follow-Up.Sample Size Reassessment and Hypothesis Testing in Adaptive Survival TrialsTesting and estimation in flexible group sequential designs with adaptive treatment selection.Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: general concepts.Adaptive designs for confirmatory clinical trials.Clinical trials for authorized biosimilars in the European Union: a systematic review.Relative efficacy of drugs: an emerging issue between regulatory agencies and third-party payers.Role of modeling and simulation in pediatric investigation plans.Twenty-five years of confirmatory adaptive designs: opportunities and pitfalls.Many-to-one comparisons after safety selection in multi-arm clinical trials.Adaptive graph-based multiple testing procedures.Estimation after blinded sample size reassessment.Do monthly or seasonal variations exist in suicides in a high-risk setting?Geriatric polytrauma.Cytotoxicity of four categories of dental cements.Cytotoxicity and shear bond strength of four orthodontic adhesive systems.Cytotoxic effects of dental bonding substances as a function of degree of conversion.Cytotoxic effects of veneer composite materials.Cytotoxicity of resin composites as a function of interface area.Cytotoxicity of a calcium aluminate cement in comparison with other dental cements and resin-based materials.IFN-gamma-enhanced allergen penetration across respiratory epithelium augments allergic inflammation.Cytotoxic effects of packable and nonpackable dental composites.Diagnostic Contribution of Donor-Specific Antibody Characteristics to Uncover Late Silent Antibody-Mediated Rejection-Results of a Cross-Sectional Screening Study.Authors' response to comments.Evidence, eminence and extrapolation.Adaptive designs for subpopulation analysis optimizing utility functions.The assessment of quality of life in a trial on lightweight mesh fixation with fibrin sealant in transabdominal preperitoneal hernia repair.A double-blind, randomized, placebo-controlled trial of intravenous L-ornithine-L-aspartate on postural control in patients with cirrhosis.Selection and bias--two hostile brothers.Osteopontin expression predicts overall survival after liver transplantation for hepatocellular carcinoma in patients beyond the Milan criteria.The risks of methodology aversion in drug regulation.[Psychosocial characteristics of victims of suicide in prisons].[Polytrauma and air rescue. A retrospective analysis of trauma care in eastern Austria exemplified by an urban trauma center].[VISCI--Viennese Instrument for Suicidality in Correctional Institutions].
P50
Q26824359-BFA95EC9-A3A5-4CEF-9303-3AE552D7AA59Q26852063-6E906DEB-205E-46A6-9693-DDAA6A95C629Q28554393-E99DD964-754C-494B-91BE-E0973DA46A43Q28595570-8671CFCD-D57C-4A79-8C1E-278795D7EE28Q28652785-15BD1B0A-A98A-45FC-BFAC-5ECB430F89DAQ31010971-9E9F9664-461E-4AAE-86A1-3E6CC30E08B0Q31091332-34D38199-EBB4-4081-A867-AC3E7D2DBB62Q35919624-0556A3EE-A237-491A-8E36-C067540735D8Q36327917-57110F7C-7302-428F-9B5A-61C7882E8A85Q36593604-D0F6BE55-2BE5-440D-BF8D-D8E12EB6D311Q37389417-80A90937-38A0-4C15-B3BA-9AE771F818BFQ37399588-66A2A825-D025-4FB1-BD53-E55B1AB0CF95Q37698958-310B960A-58C8-47FC-8780-FAC9A7A1AAC0Q37829765-16C7F244-2CFC-4F6D-814B-B4B49100FAEAQ38380750-14756BB2-1A64-4D34-917F-0EE3E334FDA8Q38708697-612A2848-F3A7-4809-BD18-3A909DE7194FQ38963322-D30462AA-750D-4C7D-B46A-94211AECEBFDQ39327135-7DAF7F4B-C078-4765-B069-4F8B356FD852Q39671591-D8C43D88-0705-4DD4-9ECB-8F40F32723ADQ39714385-591781D2-CCBB-403B-ADE8-863282877D85Q39930283-ADD8E0F5-9758-4BDC-93E1-FD03F78B105CQ39939967-09220EFB-30E3-4F4F-B580-2FFA425A4639Q39942834-7EBC7ADD-3CC2-42FA-9E24-4913C1332BE1Q40037308-D558F0F1-CA45-432F-A9EF-F404E4E31856Q40096157-86942DE4-2A65-47E5-B8A3-C5BA34ABD2F7Q40326492-DFE90268-D5C3-49CC-B305-89299D66F4ECQ40427613-5879DBB4-ECFC-44F5-9FE8-298553675B77Q40648485-610C3531-FEA6-4CBB-8350-16F5282F678FQ40779288-CD321738-95CC-4B58-98D1-8E2071059EB2Q40983087-9FCF444B-EF0B-415B-A7C1-F6F23EACB4D3Q41477325-3249ECEA-A9C4-4FC3-9EB2-75FD0B67CF71Q42250318-24204969-1DAF-4DDC-8D52-B152A16018FAQ42651120-5C071E7C-885E-4A7F-944A-ED9C7D79A57FQ43067865-C0310A1C-2179-4956-9FDB-DD06FEB51898Q43618402-DAFF1973-5785-4975-BA0A-B790A02CA63DQ43677417-D6A5C2F7-E340-45DC-BA36-FF6BCC97D55BQ43762097-5041CF3E-0939-47FD-9CFF-264C31959D0AQ43850348-DD89FDA2-DA04-4726-8CE0-0390F8BDF1C7Q43916509-C9E91E96-CB43-4903-9BCB-A521872C2D3BQ44215698-5A826DF2-9AD2-46F3-A4D1-7A58CF0FF935
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Franz König
@ast
Franz König
@en
Franz König
@es
Franz König
@sl
type
label
Franz König
@ast
Franz König
@en
Franz König
@es
Franz König
@sl
altLabel
F Koenig
@en
F König
@en
Franz Koenig
@en
prefLabel
Franz König
@ast
Franz König
@en
Franz König
@es
Franz König
@sl
P106
P1153
7007151792
P21
P31
P496
0000-0002-6893-3304